# Roivant Highlights IMVT-1402 for 85,000 Difficult-to-Treat RA Patients

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/53374
Published: 2026-11-10T22:46:05.000Z
Updated: 2026-11-10T22:46:05.000Z
Section: Business

> Roivant estimates 85,000 people have difficult-to-treat RA. At Week 28, 92.5% of the 600-milligram group maintained an ACR20 response, compared with about 75% on placebo.

Roivant highlighted IMVT-1402 and an estimated 85,000 difficult-to-treat rheumatoid arthritis patients in its Investor Day outline.

At Week 28, 92.5% of patients in the 600-milligram group maintained an ACR20 response, compared with about 75% of patients on placebo. The 300-milligram group did not preserve the response.

Roivant’s ongoing discussions with the Food and Drug Administration (FDA) cover trial design, endpoints and the number of Phase III studies.